The National Institute for Health and Care Excellence (NICE) has issued its final decision recommending Perjeta (pertuzumab) for women with HER2-positive breast cancer which has returned to the breast but is inoperable, or where it has spread to other parts of the body.
Trial data show that when Perjeta is given in combination with Herceptin and docetaxel, patients had an overall survival of 56.5 months, compared with 40.8 months for Herceptin and docetaxel alone.
Each year in the UK, 53,000 cases of breast cancer are diagnosed, and up to 25% of cases have HER2-positive disease.
Perjeta could previously only be accessed via the Cancer Drugs Fund.
Baroness Delyth Morgan, chief executive at Breast Cancer Now, said: “Perjeta’s benefits are extraordinary, offering women with incurable metastatic breast cancer over four-and-a-half years to live – nearly 16 precious extra months with their loved ones compared to existing treatments.
“We’re thrilled that tough negotiation and flexibility by NHS England and NICE, and the willingness of Roche to put patients first and compromise on price, has again ensured thousands of women can be given more time to live.”
Roche’s general manager, Richard Erwin, said: “These are positive examples of how solutions can be reached when all parties show flexibility.“